Two phase 3 trials suggest that the antibody drug conjugate led to significantly improved outcomes in both the neoadjuvant ...

Sacituzumab govitecan significantly improved survival outcomes for previously untreated, PD-L1-negative metastatic ...

The investigational PAM inhibitor extends progression-free survival from 5 to 7 months in patients with advanced, PIK3CA wild ...

Verzenio plus endocrine therapy reduced death risk by 15.8% in high-risk early breast cancer patients compared to endocrine ...

Atlantic Health, a leading provider of health care based in New Jersey, to conduct the investigator-initiated Phase 1B/2 ...

Camrelizumab/famitinib combination significantly improved PFS and OS over platinum-based chemotherapy in recurrent/metastatic ...

Patients with PD-L1-positive metastatic triple-negative breast cancer reported improved emotional function and pain with ...

BERLIN -- Administering bone-modifying agents (BMAs) every 24 weeks after long-term use was a safe and effective strategy for ...

Circulating tumor DNA (ctDNA)—genetic material shed from tumors into the bloodstream—may help risk-stratify patients with ...

Capivasertib addition to standard therapy extended rPFS by 7.5 months in PTEN-deficient metastatic hormone-sensitive prostate ...

While most of what the FDA laid out in a recent draft guidance on the assessment of overall survival in oncology clinical ...

The first iteration of HER2-targeted drugs showed limited activity in bladder cancer, but the rise of antibody-drug ...